
Sanofi: positive study data for Sarclisa
(CercleFinance.com) - Sanofi reports that in the phase III GMMG-HD7 study, its induction therapy Sarclisa significantly improved progression-free survival in transplant-eligible patients with newly diagnosed multiple myeloma.
In combination with lealidomide, bortezomib and dexamethasone (RVd), it resulted in a clinically and statistically significant reduction in disease progression or death, compared with RVd induction.
GMMG-HD7 is one of six Phase III studies to report positive results for Sarclisa in multiple myeloma (MM), including four positive results from a Sarclisa-based quadruplet in first-line treatment, the healthcare group points out.
These results reinforce Sarclisa's potential as a disease-modifying therapy when added to current standard therapy in diverse MM patient populations, and will be submitted for presentation at an upcoming medical meeting.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
In combination with lealidomide, bortezomib and dexamethasone (RVd), it resulted in a clinically and statistically significant reduction in disease progression or death, compared with RVd induction.
GMMG-HD7 is one of six Phase III studies to report positive results for Sarclisa in multiple myeloma (MM), including four positive results from a Sarclisa-based quadruplet in first-line treatment, the healthcare group points out.
These results reinforce Sarclisa's potential as a disease-modifying therapy when added to current standard therapy in diverse MM patient populations, and will be submitted for presentation at an upcoming medical meeting.
Copyright (c) 2024 CercleFinance.com. All rights reserved.